{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T03:23:23Z","timestamp":1781580203915,"version":"3.54.5"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Cardiac amyloidosis is frequently misdiagnosed, denying patients the opportunity for timely and appropriate management of the disease. The purpose of this review and case studies is to raise awareness of the diagnostic \u201cred flags\u201d associated with cardiac amyloidosis and the currently available non-invasive strategies for diagnosis. The review focuses on the identification of one of the two main types of cardiac amyloidosis, transthyretin amyloid cardiomyopathy, and non-invasive tools to distinguish this from light-chain amyloidosis. A diagnostic algorithm centered around the use of non-invasive imaging and laboratory analysis is presented. The algorithm generates four differential diagnoses for patients presenting with signs and symptoms consistent with cardiac amyloidosis. Case examples are presented, representing the four potential outcomes of diagnosis using the algorithm. The review provides a guide on how to recognize the often-overlooked presentations of this disease in clinical practice. Non-invasive imaging techniques and diagnostic tools that do not require the involvement of a specialty center have allowed for the improved diagnosis of cardiac amyloidosis. Timely diagnosis of this life-threatening disease is essential for optimal management and it is imperative that clinicians have a high index of suspicion for patients presenting with \u201cred flag\u201d symptoms.<\/jats:p>","DOI":"10.3389\/fcvm.2021.644508","type":"journal-article","created":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T06:52:46Z","timestamp":1624603966000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["From Clinical Clues to Final Diagnosis: The Return of Detective Work to Clinical Medicine in Cardiac Amyloidosis"],"prefix":"10.3389","volume":"8","author":[{"given":"Hani","family":"Sabbour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khwaja Yousuf","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firas","family":"Al Badarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haluk","family":"Alibazoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Rivard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingy","family":"Romany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Perlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American heart association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation."},{"key":"B2","doi-asserted-by":"publisher","first-page":"s30","DOI":"10.7861\/clinmedicine.18-2-s30","article-title":"Cardiac amyloidosis","volume":"18","author":"Martinez-Naharro","year":"2018","journal-title":"Clin Med Lond Engl."},{"key":"B3","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","article-title":"Screening for transthyretin amyloid cardiomyopathy in everyday practice","volume":"7","author":"Witteles","year":"2019","journal-title":"JACC Heart Fail."},{"key":"B4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4081\/itjm.2019.1149","article-title":"Cardiac amyloidosis: a review of the literature and a practical approach for the clinicians","volume":"13","author":"Angelini","year":"2019","journal-title":"Ital J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","article-title":"Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis","volume":"135","author":"Maurer","year":"2017","journal-title":"Circulation."},{"key":"B6","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/bjh.12286","article-title":"Systemic amyloidosis in England: an epidemiological study","volume":"161","author":"Pinney","year":"2013","journal-title":"Br J Haematol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1080\/07853890701842988","article-title":"Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study","volume":"40","author":"Tanskanen","year":"2008","journal-title":"Ann Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","article-title":"Epidemiology of AL amyloidosis: a real-world study using US claims data","volume":"2","author":"Quock","year":"2018","journal-title":"Blood Adv."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2021.1898365","article-title":"Incidence of light chain amyloidosis in florence metropolitan area, Italy: a population-based study","volume":"10","author":"Zampieri","year":"2021","journal-title":"Amyloid."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Casta\u00f1o","year":"2017","journal-title":"Eur Heart J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.cjca.2019.12.033","article-title":"Amyloidosis as a systemic disease in context","volume":"36","author":"Cuddy","year":"2020","journal-title":"Can J Cardiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e006075","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail."},{"key":"B14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3949\/ccjm.84.s3.02","article-title":"Cardiac amyloidosis: an update on diagnosis and treatment","volume":"84","author":"Donnelly","year":"2017","journal-title":"Cleve Clin J Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"8552","DOI":"10.1038\/s41598-019-44912-x","article-title":"Predictors of mortality in light chain cardiac amyloidosis with heart failure","volume":"9","author":"Tahir","year":"2019","journal-title":"Sci Rep."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/eurheartj\/ehx043","article-title":"Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths","volume":"38","author":"Gonz\u00e1lez-L\u00f3pez","year":"2017","journal-title":"Eur Heart J."},{"key":"B18","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1016\/j.cardfail.2019.07.197","article-title":"Amyloidosis research consortium cardiac amyloidosis survey: results from patients with AL and ATTR amyloidosis and their caregivers","volume":"25","author":"Lousada","year":"2019","journal-title":"J Card Fail."},{"key":"B19","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10741-014-9462-7","article-title":"Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs","volume":"20","author":"Casta\u00f1o","year":"2015","journal-title":"Heart Fail Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s12872-018-0952-8","article-title":"Diagnosis of cardiac amyloidosis: a systematic review on the role of imaging and biomarkers","volume":"18","author":"Kyriakou","year":"2018","journal-title":"BMC Cardiovasc Disord."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1177\/2047487319877708","article-title":"Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings","volume":"27","author":"Vergaro","year":"2020","journal-title":"Eur J Prev Cardiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1161\/CIRCULATIONAHA.113.006242","article-title":"Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis","volume":"129","author":"Quarta","year":"2014","journal-title":"Circulation."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1161\/CIRCULATIONAHA.104.489187","article-title":"Diagnosis and management of the cardiac amyloidoses","volume":"112","author":"Falk","year":"2005","journal-title":"Circulation."},{"key":"B26","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40119-020-00169-4","article-title":"Diagnosis of transthyretin amyloid cardiomyopathy","volume":"9","author":"Hafeez","year":"2020","journal-title":"Cardiol Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat Rev Dis Primer."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.15353.1","article-title":"Recent advances in understanding and treating immunoglobulin light chain amyloidosis","volume":"7","author":"Badar","year":"2018","journal-title":"F1000Research."},{"key":"B29","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jacbts.2019.02.002","article-title":"Emerging therapeutics for the treatment of light chain and transthyretin amyloidosis","volume":"4","author":"Zhang","year":"2019","journal-title":"JACC Basic Transl Sci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1080\/13506129.2018.1436048","article-title":"Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR)","volume":"25","author":"Phull","year":"2018","journal-title":"Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis."},{"key":"B31","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jaccao.2019.08.002","article-title":"AL amyloidosis for the cardiologist and oncologist: epidemiology, diagnosis, and management","volume":"1","author":"Witteles","year":"2019","journal-title":"JACC CardioOncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s11897-019-00446-x","article-title":"Amyloidosis in heart failure","volume":"16","author":"Ihne","year":"2019","journal-title":"Curr Heart Fail Rep."},{"key":"B33","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1161\/CIRCIMAGING.112.000132","article-title":"(99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses","volume":"6","author":"Bokhari","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1007\/s12350-019-01760-6","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging","volume":"26","author":"Dorbala","year":"2019","journal-title":"J Nucl Cardiol Off Publ Am Soc Nucl Cardiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J."},{"key":"B36","unstructured":"Tc-99m-PYP planar scan pitfalls in the assessment of cardiac amyloidosis1370\n            AlkordyT\n            RomsaGJ\n            AkinciogluC\n          J Nucl Med.612020"},{"key":"B37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0002-9149(82)90270-3","article-title":"Amyloid cardiomyopathy: characterization by a distinctive voltage\/mass relation","volume":"49","author":"Carroll","year":"1982","journal-title":"Am J Cardiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3109\/13506129.2015.1135792","article-title":"Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis","volume":"23","author":"Nakagawa","year":"2016","journal-title":"Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis."},{"key":"B39","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3109\/03009734.2014.895786","article-title":"Transthyretin-derived amyloidosis: Probably a common cause of lumbar spinal stenosis","volume":"119","author":"Westermark","year":"2014","journal-title":"Ups J Med Sci."},{"key":"B40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1185\/03007995.2012.754348","article-title":"THAOS - the transthyretin amyloidosis outcomes survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis","volume":"29","author":"Coelho","year":"2013","journal-title":"Curr Med Res Opin."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/jns.12403","article-title":"Peripheral neuropathy symptoms in wild type transthyretin amyloidosis","volume":"25","author":"Yungher","year":"2020","journal-title":"J Peripher Nerv Syst."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.644508\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T13:59:18Z","timestamp":1624888758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.644508\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,25]]},"references-count":43,"alternative-id":["10.3389\/fcvm.2021.644508"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.644508","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,25]]},"article-number":"644508"}}